The findings could help clinicians use neuropsychiatric symptoms to prepare patients and families for a type of dementia ...

New Assay Expands INDIGO’s GPCR Portfolio and Supports Development of Next-Generation CNS-Related Therapeutics STATE ...

People with Alzheimer's disease often have other neurodegenerative conditions as well, including a less-understood disorder ...

Alto Neuroscience secures $120M to advance novel depression therapy ALTO-207 through Phase 3 trials, aiming for FDA ...

A mouse study highlights the role of acetylcholine in behavioral flexibility, offering new insight into the brain mechanisms involved in addiction and obsessive compulsive disorder.

The Missouri Senate is considering a bill that would make insurance companies cover treatments for certain pediatric ...

For decades, one of the greatest challenges to treating neurological disorders like attention-deficit/hyperactivity disorder is that its symptoms often resemble those of several other conditions.

Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 ...

People with Alzheimer's disease often have other neurodegenerative conditions as well, including a less-understood disorder called frontotemporal lobar degeneration (FTLD).

The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a ...

Researchers say discovery could establish the basis for a novel, tandem biomarker-peptide therapeutic approach to schizophrenia.

Rutgers Brain Health Institute supports students through federally funded training grants, scholar programs, and ...